Lantern Pharma Closes $4M Registered Direct Offering with Warrants
LTRN is trading near its 52-week low of $0.97 (4.1% above the low) on elevated volume (2.4× avg).
Summary
Lantern Pharma closed a $4M registered direct offering at $1.09/share with pre-funded and purchase warrants, adding placement agent fees and stockholder approval requirements.
Key Events · Financing and Capital Events · LTRN
-
Offering Closed
Closed $4M registered direct offering on September 30, 2026: 1,469,725 common shares at $1.09 plus 2,200,000 pre-funded warrants at $1.0899.
-
Warrant Overhang
Issued 3,669,725 purchase warrants at $1.09 exercise price in concurrent private placement, exercisable only after stockholder approval, expiring 5 years post-approval.
-
Placement Agent Terms
Rodman & Renshaw received 7% cash fee, 5% warrant coverage (exercise price $1.3625), and 3% fee on future warrant exercises.
-
Stockholder Approval Required
Company must seek stockholder approval within 90 days for warrant share issuance; if not obtained, must call meetings every 90 days until approval or warrants expire.
Analysis · LTRN · Life Sciences
Lantern Pharma closed a $4 million registered direct offering at $1.09 per share, issuing 1,469,725 common shares and 2,200,000 pre-funded warrants, plus 3,669,725 purchase warrants in a concurrent private placement. The deal adds material new terms: Rodman & Renshaw received a 7% cash fee, 5% warrant coverage, and a 3% fee on future warrant exercises. The company must seek stockholder approval within 90 days to allow warrant exercise, and file a resale registration statement within 30 days. Against a backdrop of a going-concern warning from the Q2 10-Q and a stock trading near its 52-week low, this capital raise provides runway but carries significant potential dilution if all warrants are exercised.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.97 to $4.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.